Core Viewpoint - Hanx Biopharmaceuticals (Wuhan) Co., Ltd. is launching an IPO with a total offering of 18.321 million H-shares, aiming for a listing on the Hong Kong Stock Exchange on December 23, 2025, with ICBC International as the sole sponsor [2][3]. Offering Details - The IPO will consist of 18.321 million H-shares, with 1.8321 million shares available for reallocation and 16.4889 million shares for international offering [3]. - The maximum offering price is set at HKD 32.00 per share, with additional fees including a 1% brokerage commission and various transaction fees [3]. - The offering period is from December 15 to December 18, 2025, and the expected net proceeds are approximately HKD 4.96 billion [4][5]. Use of Proceeds - Approximately 35% of the net proceeds will be allocated to the development of the core product HX009, while 33% will be used for the main products HX301 and HX044 [5]. - Additional allocations include 17% for other important product developments, 5% for commercialization and business development activities, and 10% for working capital and general corporate purposes [5]. Shareholder Structure - The major shareholders include Dr. Zhang Faming with 40.60% and other entities holding significant stakes, resulting in a total of 55.89% ownership by major shareholders [7]. - The public offering accounts for 13.45% of the total shares [4]. Company Overview - Hanx Biopharmaceuticals focuses on discovering, developing, and commercializing innovative therapies for cancer and autoimmune diseases, with a pipeline of 10 drug candidates [7]. - The company has developed core products including HX009, a PD-1/SIRPα dual-function antibody fusion protein, and is advancing several candidates in clinical and preclinical stages [7].

Group 1 - The core viewpoint of the article is that Hansai Aitai Biopharmaceutical Technology (Wuhan) Co., Ltd. has submitted its Hong Kong IPO prospectus, which has now expired after six months [1] - The company specializes in structural biology, translational medicine, and clinical development, showcasing its expertise and experience in these fields [2] - Since 2016, the company has been developing an innovative pipeline that includes one core product and nine other candidate products, focusing on oncology and autoimmune markets [2] Group 2 - The pipeline includes three clinical-stage candidates for oncology, namely the core product HX009 and major products HX301 and HX044 [2] - Additionally, there are seven preclinical candidates, which consist of antibody-drug conjugates, bispecific antibodies, and monoclonal antibodies targeting autoimmune and oncology markets [2] - The company has previously developed HX008, which has been transferred to a biopharmaceutical company focused on oncology therapies [2]

Core Viewpoint - Hanx Biopharmaceuticals (Wuhan) Co., Ltd. plans to issue up to 21,069,700 overseas listed ordinary shares and convert 117,897,830 domestic unlisted shares into overseas listed shares for trading on the Hong Kong Stock Exchange [1] Company Overview - Hanx Biopharmaceuticals is an innovative biotech company specializing in structural biology, translational medicine, and clinical development, with a focus on building an innovative pipeline since 2016 [1] - The company has developed a core product and nine other pipeline candidates, including three clinical-stage candidates targeting oncology (HX009, HX301, HX044) and seven preclinical candidates, which include antibody-drug conjugates, bispecific antibodies, and monoclonal antibodies targeting autoimmune and oncology markets [1] Shareholder Information - A total of 15 shareholders will convert their shares, with the largest shareholding being 55,300,000 shares from Cai Zhang Biotechnology (Hangzhou) Co., Ltd. [2] - Other significant shareholders include Hanx Biopharmaceuticals (HK) Limited with 17,793,640 shares and Beijing Longpan Biopharmaceutical Venture Capital Center (Limited Partnership) with 12,860,470 shares [2] - The total number of shares being converted amounts to 117,897,830 shares [2]

Core Viewpoint - Hanse Aitai Biopharmaceutical Technology (Wuhan) Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with ICBC International as the sole sponsor, despite being in a loss-making position for the fiscal years 2023 and 2024 [1][4]. Company Overview - Hanse Aitai is an innovative biotechnology company specializing in structural biology, translational medicine, and clinical development, with a pipeline that includes one core product and nine other candidate products [4][6]. - The core product, HX009, is a self-developed PD-1/SIRPα dual-function antibody fusion protein, which has completed Phase I clinical trials in Australia and China [4][5]. Product Pipeline - The company has three ongoing clinical projects for HX009 in China, targeting advanced melanoma, relapsed/refractory Epstein-Barr virus-positive non-Hodgkin lymphoma, and advanced biliary tract cancer [5]. - Two other major products, HX301 and HX044, are in clinical stages, focusing on cancer treatment. HX301 is a multi-target kinase inhibitor, while HX044 is a novel dual-function anti-CTLA-4 antibody SIRPα fusion protein [5][6]. Financial Performance - For the fiscal years 2023 and 2024, the company reported other income and revenue of approximately RMB 6.664 million and RMB 7.681 million, respectively, while incurring losses of about RMB 85.16 million and RMB 117 million [6][8]. - The company has a total of ten candidate drugs in its pipeline, with eight targeting oncology and two for autoimmune diseases [6].